21-hydroxylase deficiency medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 17: Line 17:


====Long-term management of congenital adrenal hyperplasia====
====Long-term management of congenital adrenal hyperplasia====
Management of infants and children with congenital adrenal hyperplasia is complex and warrants long term care in a [[pediatric endocrinology|pediatric endocrine clinic]]. After the diagnosis is confirmed, and any salt-wasting crisis averted or reversed, major management issues include:<ref name="pmid275213">{{cite journal| author=Schwartz LJ| title=Have you told your laboratory man you love him? | journal=Ill Dent J | year= 1977 | volume= 46 | issue= 6 | pages= 281 | pmid=275213 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=275213  }} </ref>
Management of infants and children with congenital adrenal hyperplasia is complex and warrants long term care in a [[pediatric endocrinology|pediatric endocrine clinic]]. After the diagnosis is confirmed, and any salt-wasting crisis averted or reversed, major management issues include:
*Initiating and monitoring hormone replacement
*Initiating and monitoring hormone replacement
*Stress coverage, crisis prevention, parental education
*Stress coverage, crisis prevention, parental education

Revision as of 18:00, 15 October 2015

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

21-hydroxylase deficiency medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 21-hydroxylase deficiency medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 21-hydroxylase deficiency medical therapy

CDC on 21-hydroxylase deficiency medical therapy

21-hydroxylase deficiency medical therapy in the news

Blogs on 21-hydroxylase deficiency medical therapy

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Risk calculators and risk factors for 21-hydroxylase deficiency medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

The mainstay of therapy for congenital adrenal hyperplasia due to 21-hydroxylase deficiency is glucocorticoid replacement.

Medical Therapy

The mainstay of therapy for congenital adrenal hyperplasia due to 21-hydroxylase deficiency is glucocorticoid replacement.

Early-onset: Severe 21-hydroxylase deficient congenital adrenal hyperplasia

Salt-wasting crisis in infancy

Long-term management of congenital adrenal hyperplasia

Management of infants and children with congenital adrenal hyperplasia is complex and warrants long term care in a pediatric endocrine clinic. After the diagnosis is confirmed, and any salt-wasting crisis averted or reversed, major management issues include:

  • Initiating and monitoring hormone replacement
  • Stress coverage, crisis prevention, parental education
  • Reconstructive surgery
  • Optimizing growth
  • Optimizing androgen suppression and fertility in women with congenital adrenal hyperplasia
Hormone replacement
  • Glucocorticoids provide a reliable substitute for cortisol and reduce ACTH level. Reducing ACTH also reduces the stimulus for continued hyperplasia and overproduction of androgens in both sexes.[1]
  • Hydrocortisone or liquid prednisolone is preferred in infancy and childhood.
  • Prednisone or dexamethasone are often more convenient for adults.
  • Dose is typically started at the low end of physiologic replacement (6-12 mg/m2) but is adjusted throughout childhood to prevent both growth suppression from too much and androgen escape from too little glucocorticoid.
  • Serum levels of 17OHP, testosterone, androstenedione, and other adrenal steroids are followed for additional information, but may not be entirely normalized even with optimal treatment.

Optimizing growth in congenital adrenal hyperplasia

Childhood onset (simple virilizing) congenital adrenal hyperplasia

The mainstay of treatment is:[1]

Late onset (nonclassical) congenital adrenal hyperplasia

  • Combination of very low dose of glucocorticoid (to reduce adrenal androgen production) and androgen blockers (to induce ovulation) are used in late onset congenital adrenal hyperplasia.[1]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_21-hydroxylase_deficiency
  2. Migeon CJ, Wisniewski AB (2001). "Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Growth, development, and therapeutic considerations". Endocrinol Metab Clin North Am. 30 (1): 193–206. PMID 11344936.

Template:WikiDoc Sources